Oxytocin Shortage
Frequently Asked Questions
Frequently Asked Questions
-
Last updated October 21, 2022
Yes, but the shortage is affecting hospitals and regions differently. The FDA Drug Shortage Program requires notification of shortages of medically necessary products that could have a significant impact on public health. Two major manufacturers and several small compounding pharmacies currently supply oxytocin in the United States. On September 23, 2022, one of the major manufacturers reported a manufacturing delay of certain-size vials of oxytocin1. Some hospitals and regions have noticed a shortage already whereas other areas have not experienced a shortage.
-
Last updated October 21, 2022
When medication supply backorders occur, the FDA notifies end users of products of pending shortage delays. While categories are listed by the FDA for reasons for a drug shortage, the specific explanation is not delineated. This could be due to factors such as requirements related to complying with good manufacturing practices, regulatory delay, a shortage of an active ingredient, shortage of an inactive ingredient component, discontinuation of the manufacture of the drug, delay in shipping of the drug, or a demand increase for the drug.
-
Last updated January 12, 2023 at 9:30 a.m. ET
The FDA webpage indicates lack of availability from one manufacturer with the next expected release in January 2023, and limited availability from another manufacturer1.
-
Last updated October 21, 2022
Oxytocin is utilized for a variety of purposes during labor; alternative medications are available for many of these situations. With thoughtful planning, risks to individual patients should be minimized. As processes and outcomes of care are known to vary by patient population and institutional resources, applying equitable solutions will be important to avoid widening of existing disparities.
-
Last updated October 21, 2022
Until the oxytocin supply shortage has been resolved, each facility may need to establish a cross-departmental team (pharmacy, obstetric and anesthesia care professionals, nursing leadership, etc.) and an action plan to optimize the use of oxytocin. Examples of interventions could include the following:
Antepartum
- Develop a hierarchy of scheduled and unscheduled inductions as needed and create ongoing processes of review.
- Consider specific indications and contraindications to uterotonics during stratification of individual risk for postpartum hemorrhage based on historical factors.
Intrapartum
- Consider delineating admission criteria for active labor, for example, minimal cervical dilation of 4 cm.
- Use cervical ripening agents for inductions of labor when the Bishop score is not favorable to maximize the Bishop score prior to initiating oxytocin to reduce overall usage. For example, consider use of a balloon with misoprostol for cervical ripening rather than concomitant use with oxytocin.
- Enhance active management of labor, inclusive of amniotomy, to minimize need for pharmacologic augmentation, shorten time to delivery, and minimize hemorrhage risk.
- Stratify and update individual risk for postpartum hemorrhage, with anticipatory planning for management. An example of an approach to stratifying risk is found in ACOG Practice Bulletin No 183, Table 22.
- Limit wasting of the labor oxytocin infusion bag after delivery by using the same infusion bag for the same patient for postpartum hemorrhage prophylaxis, as needed.
Postpartum
- Consider 10 U, IM, oxytocin postpartum for hemorrhage prophylaxis.
- Alternatively, consider replacing oxytocin infusion with one-time doses of alternative uterotonics such as methylergonovine, 15-methyl prostaglandin F2α, or misoprostol, depending on patient risk factors. An example of medication options is found in ACOG Practice Bulletin No 183, Table 32.
- When postpartum hemorrhage has occurred, consider using two doses of uterotonics (either methylergonovine, 15-methl prostaglandin F2α, or misoprostol), advancing to oxytocin infusion only after these therapies are deployed. When initial medical therapy fails, tranexamic acid should be considered.
Additional Potential Actions to Implement
- Avoid routine use of oxytocin for first trimester dilation and curettage.
- Develop mechanisms for daily oversight and accountability to ensure tighter control of current inventory (anesthesia carts, main OR, ED, etc.).
Please contact [email protected] with any questions.
References
- U.S. Food and Drug Administration. Current and resolved drug shortages and discontinuations reported to FDA: oxytocin injection. FDA Drug Shortages. Accessed October 18, 2022. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Oxytocin%20Injection&st=c
- Postpartum hemorrhage. Practice Bulletin No. 183. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e168–86. DOI: 10.1097/AOG.0000000000002351.
This document has been developed to respond to some of the questions facing clinicians providing care during the evolving oxytocin shortage situation. As the situation evolves, this document may be updated or supplemented to incorporate new data and relevant information. This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence. Any updates to this document can be found on acog.org or by calling the ACOG Resource Center.
While ACOG makes every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
All ACOG committee members and authors have submitted a conflict of interest disclosure statement related to this published product. Any potential conflicts have been considered and managed in accordance with ACOG’s Conflict of Interest Disclosure Policy. The ACOG policies can be found on acog.org. For products jointly developed with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product.